Reshaping the HIV treatment and prevention landscape
Key growth drivers: 2021-26
Vaccines
Shingrix
Specialty Medicines
Zejula, Blenrep, Jemperli*
Meningitis
(Bexsero, Menveo, Men ABCWY)
RSV OA
High single digit % sales CAGR
Dovato, Cabenuva, Cab PrEP
Nucala, Benlysta, depemokimab ('294)
gepotidacin
daprodustat
Double digit % sales CAGR
General Medicines
Trelegy
Broadly stable sales
gsk
All outlook and ambition statements are given on a constant currency basis and use 2021 forecast exchange rates as a base, assuming a continuation of Q1 2021 closing rates. See basis of preparation and assumptions in Appendix. CAGR is for
the 5 years to 2026, using 2021 as the base year. Pipeline sales are risk-adjusted and include anticipated sales of new products and Life Cycle Innovation (LCI) launched from 2021 onwards. Note: COVID therapeutic and vaccine solutions are
excluded from the above. Italicised assets are selected expected approvals in 2021-2026 period
*Tesaro asset
36View entire presentation